Clinic
Montefiore Medical Center
Montefiore Medical Center was paid $8.13M by Medicaid between Jan 2018 and Mar 2023, across 252 billing codes. Its largest line is 90832, psychotherapy session, about 30 minutes — 7.9% of everything it billed.
33Billing provider infoMONTEFIORE MEDICAL CENTER
BRONX, NY 10467
BRONX, NY 10467
33aNPI1659446680assigned 11/22/2006
33bProvider typeFederally Qualified Health Center (FQHC)
28Total paid$8.13M
24GClaims248,104
24DCodes billed252
24AFirst – last monthJan 2018 – Mar 2023
Compared with peers
Next to other Federally Qualified Health Center (FQHC) providers in New York
Rank by total paid#39 of 158
Median peer was paid$1.73M
This provider vs. median4.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26 | $0.00 | |
| 2019 | 30,974 | $1.44M | |
| 2020 | 58,184 | $1.67M | |
| 2021 | 71,827 | $2.02M | |
| 2022 | 65,494 | $2.16M | |
| 2023 | 21,599 | $834K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 7.9% | 4,973 | 3,356 | $638K |
| 80053 | Comprehensive metabolic panel | 7.0% | 13,031 | 12,135 | $569K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.5% | 7,311 | 6,044 | $369K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.3% | 3,378 | 2,903 | $348K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.6% | 1,075 | 867 | $295K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.3% | 159 | 117 | $268K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 284 | 260 | $252K |
| 36415 | Collection of venous blood by venipuncture | 3.0% | 4,139 | 3,899 | $241K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 921 | 852 | $237K |
| 81001 | 2.9% | 3,912 | 3,732 | $237K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 2.8% | 1,552 | 1,363 | $227K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.6% | 3,734 | 3,532 | $210K |
240 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.5% | 1,110 | $204K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 1,393 | $195K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 4,702 | $190K |
| 99214 | Doctor's office visit, returning patient (more involved) | 2.2% | 1,386 | $181K |
| 86850 | 2.2% | 2,024 | $181K | |
| 90834 | Psychotherapy session, about 45 minutes | 2.0% | 1,024 | $161K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 1,070 | $140K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 1,659 | $131K |
| 87806 | 1.6% | 2,284 | $130K | |
| 87631 | 1.5% | 1,362 | $121K | |
| 86480 | 1.5% | 1,087 | $119K | |
| 80061 | Lipid panel | 1.3% | 9,459 | $107K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 1,588 | $105K |
| 81003 | 1.2% | 1,772 | $99K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 3,318 | $95K |
| 99283 | Emergency room visit (moderate) | 1.0% | 1,846 | $84K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,823 | $78K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 537 | $65K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,127 | $64K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 494 | $61K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,566 | $58K |
| 87081 | <1% | 1,165 | $55K | |
| 86900 | <1% | 2,032 | $51K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,237 | $50K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 426 | $49K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 414 | $47K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 264 | $47K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 341 | $45K |
| 86769 | <1% | 741 | $42K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,432 | $41K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 251 | $39K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 160 | $38K |
| 86901 | <1% | 2,032 | $38K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,223 | $37K |
| 99284 | Emergency room visit (serious) | <1% | 1,101 | $37K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 736 | $35K |
| 92551 | <1% | 669 | $35K | |
| 82948 | <1% | 843 | $33K | |
| 86780 | <1% | 2,926 | $32K | |
| 87481 | <1% | 199 | $30K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,702 | $30K |
| 80076 | <1% | 1,783 | $29K | |
| 82728 | <1% | 2,653 | $29K | |
| 90686 | <1% | 1,965 | $25K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 121 | $24K |
| 83655 | <1% | 1,128 | $23K | |
| 82784 | <1% | 596 | $23K | |
| 87486 | <1% | 78 | $21K | |
| 87070 | <1% | 376 | $21K | |
| 83021 | <1% | 547 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 26 | $20K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 811 | $20K |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 224 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,898 | $19K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 249 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 476 | $15K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 134 | $14K |
| 0002A | <1% | 362 | $14K | |
| 0001A | <1% | 418 | $14K | |
| 84439 | <1% | 3,473 | $14K | |
| 90836 | <1% | 82 | $14K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 205 | $14K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 139 | $13K |
| 84702 | <1% | 1,848 | $13K | |
| 82607 | <1% | 2,188 | $13K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 88 | $13K |
| 85610 | <1% | 2,140 | $11K | |
| 87077 | <1% | 694 | $11K | |
| 86803 | <1% | 2,331 | $11K | |
| 99285 | Emergency room visit (most serious) | <1% | 674 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,934 | $11K |
| 86359 | <1% | 87 | $11K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 247 | $10K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 55 | $10K |
| 96127 | <1% | 1,372 | $10K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 56 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 265 | $9K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,163 | $9K |
| 87490 | <1% | 1,587 | $9K | |
| 83735 | <1% | 2,185 | $9K | |
| 82330 | <1% | 1,258 | $9K | |
| 84466 | <1% | 2,362 | $8K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,447 | $8K |
| 90670 | <1% | 335 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,183 | $7K |
| 83615 | <1% | 842 | $7K | |
| 86140 | <1% | 972 | $7K | |
| 83540 | <1% | 2,447 | $6K | |
| 97010 | <1% | 106 | $6K | |
| 87205 | <1% | 377 | $6K | |
| 90651 | <1% | 214 | $6K | |
| 0003A | <1% | 154 | $6K | |
| 73630 | <1% | 48 | $6K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,681 | $6K |
| 87581 | <1% | 78 | $5K | |
| 92557 | <1% | 44 | $5K | |
| 82043 | <1% | 1,661 | $5K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,184 | $4K |
| 84100 | <1% | 1,315 | $4K | |
| 86706 | <1% | 1,089 | $4K | |
| 82565 | <1% | 227 | $4K | |
| 82550 | <1% | 1,338 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,957 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 46 | $4K |
| 90734 | <1% | 203 | $3K | |
| 85046 | <1% | 281 | $3K | |
| 82785 | <1% | 101 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $3K |
| 86704 | <1% | 415 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $3K |
| 84484 | <1% | 1,139 | $2K | |
| 83690 | <1% | 1,343 | $2K | |
| J3490 | Unclassified drugs | <1% | 1,548 | $2K |
| 82570 | <1% | 2,098 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 708 | $2K |
| 82746 | <1% | 859 | $2K | |
| 83880 | <1% | 277 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 40 | $2K |
| 84153 | <1% | 315 | $2K | |
| 84550 | <1% | 816 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 492 | $2K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 33 | $2K |
| 99173 | <1% | 26 | $2K | |
| 86592 | <1% | 29 | $2K | |
| 83605 | <1% | 1,243 | $2K | |
| 87340 | <1% | 1,820 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,262 | $2K |
| 90715 | <1% | 219 | $2K | |
| 82375 | <1% | 1,243 | $2K | |
| 83970 | <1% | 182 | $2K | |
| 83001 | <1% | 212 | $2K | |
| 85730 | <1% | 1,787 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 15 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 30 | $2K |
| 76770 | <1% | 29 | $1K | |
| 95117 | <1% | 65 | $1K | |
| 86696 | <1% | 13 | $1K | |
| 0124A | <1% | 94 | $1K | |
| 84520 | <1% | 189 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 65 | $1K |
| 86735 | <1% | 459 | $1K | |
| 93970 | <1% | 25 | $1K | |
| 84703 | <1% | 63 | $1K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 19 | $1K |
| 86762 | <1% | 648 | $1K | |
| 82947 | <1% | 1,564 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,375 | $1K |
| 90680 | <1% | 146 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 56 | $1K |
| 85044 | <1% | 551 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 147 | $1K |
| 73610 | <1% | 14 | $1K | |
| 82150 | <1% | 260 | $1K | |
| 90633 | <1% | 136 | $971.15 | |
| 92083 | <1% | 12 | $965.30 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 923 | $913.86 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 830 | $894.83 |
| 86360 | <1% | 87 | $842.30 | |
| 84295 | <1% | 1,407 | $829.69 | |
| 0011A | <1% | 20 | $800.00 | |
| 0012A | <1% | 20 | $795.00 | |
| 73560 | <1% | 13 | $756.39 | |
| 82800 | <1% | 1,239 | $747.93 | |
| 84403 | <1% | 203 | $740.20 | |
| 85652 | <1% | 929 | $719.50 | |
| 84146 | <1% | 109 | $699.33 | |
| 86038 | <1% | 310 | $680.95 | |
| 86200 | <1% | 13 | $672.83 | |
| 92567 | <1% | 51 | $642.53 | |
| 99385 | <1% | 16 | $583.54 | |
| 83050 | <1% | 1,243 | $574.45 | |
| 86765 | <1% | 694 | $565.31 | |
| 87088 | <1% | 788 | $448.25 | |
| 82310 | <1% | 52 | $446.12 | |
| 84132 | <1% | 1,156 | $440.24 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,371 | $439.59 |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 12 | $377.35 |
| 86787 | <1% | 592 | $376.17 | |
| 86003 | <1% | 163 | $364.96 | |
| 80197 | <1% | 64 | $358.97 | |
| 90696 | <1% | 16 | $346.45 | |
| 90698 | <1% | 27 | $329.77 | |
| 81025 | <1% | 12 | $313.22 | |
| 82465 | <1% | 88 | $306.76 | |
| 85651 | <1% | 197 | $284.01 | |
| 90723 | <1% | 25 | $279.64 | |
| 90750 | <1% | 12 | $275.91 | |
| 90710 | <1% | 67 | $254.24 | |
| 86708 | <1% | 53 | $245.69 | |
| 90648 | <1% | 13 | $236.69 | |
| 87186 | <1% | 337 | $235.88 | |
| 84156 | <1% | 594 | $233.82 | |
| 76642 | <1% | 18 | $195.04 | |
| 84436 | <1% | 27 | $194.00 | |
| 84155 | <1% | 86 | $161.99 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 834 | $154.37 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 576 | $145.92 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 250 | $138.60 |
| 82977 | <1% | 30 | $134.00 | |
| 87536 | <1% | 68 | $119.42 | |
| H0049 | Alcohol and/or drug screening | <1% | 188 | $114.25 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $109.56 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 882 | $108.92 |
| 83520 | <1% | 14 | $89.15 | |
| 87563 | <1% | 38 | $86.55 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 32 | $79.42 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 319 | $78.15 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,193 | $55.79 |
| 87147 | <1% | 14 | $55.00 | |
| 84402 | <1% | 77 | $35.98 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,081 | $33.62 |
| 86161 | <1% | 12 | $26.48 | |
| 90697 | <1% | 13 | $17.85 | |
| 86225 | <1% | 27 | $15.09 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 12 | $11.97 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 583 | $3.44 |
| 91312 | <1% | 79 | $1.08 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 60 | $0.74 |
| 91313 | <1% | 13 | $0.13 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 70 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 71 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 48 | $0.00 |
| 86376 | 0% | 25 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 128 | $0.00 |
| 84480 | 0% | 26 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 18 | $0.00 |
| 86141 | 0% | 15 | $0.00 | |
| 83002 | 0% | 39 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 45 | $0.00 |
| 85362 | 0% | 12 | $0.00 | |
| 86431 | 0% | 105 | $0.00 | |
| 83516 | 0% | 64 | $0.00 | |
| 81513 | 0% | 198 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 50 | $0.00 |
| 86618 | 0% | 12 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 102 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 13 | $0.00 |
| 99051 | 0% | 26 | $0.00 | |
| 76857 | 0% | 15 | $0.00 | |
| 90662 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPERLMAN, JOEL (CHIEF FINANCIAL OFFICER)
Parent organizationMONTEFIORE MEDICAL CENTER